The purpose of this study is to compare the results of two different sleep tests in Alzheimer's patients with no symptoms or early symptoms. Participants will undergo two simultaneous sleep tests (polysomnography) in a sleep laboratory for two nights and one sleep test at home for three nights. For each participant, the study will last at least a week and will last up to three months.
Have mild cognitive impairment, subjective memory complaints, or normal cognition.
Evidence of the presence of Alzheimer's pathology as measured by amyloid positron emission tomography (PET), cerebrospinal fluid biomarkers (amyloid beta and tau), or blood biomarkers.
Montreal Cognitive Assessment (MoCA) score of 24 or greater.
Clinical Dementia Rating Scale (CDR) global score of 0 or 0.5.
Severe illness that in the investigator's judgement would adversely affect the participant's participation in the study.
Skin illness that may interfere with study assessments.
Has a pacemaker or implantable cardioverter defibrillator.
Diagnosed with a sleep disorder.